St. Jude Medical Inc. (NYSE:STJ) shares hit a new 52-week high on Monday . The company traded as high as $83.80 and last traded at $83.40, with a volume of 758,039 shares trading hands. The stock had previously closed at $83.04.

A number of brokerages have recently weighed in on STJ. Zacks Investment Research lowered St. Jude Medical from a “buy” rating to a “hold” rating in a report on Friday, July 22nd. Canaccord Genuity set a $85.00 price objective on St. Jude Medical and gave the company a “hold” rating in a report on Wednesday, July 20th. Barclays PLC increased their price objective on St. Jude Medical from $80.00 to $83.00 and gave the company an “equal weight” rating in a report on Thursday, July 21st. Leerink Swann reissued a “hold” rating and issued a $85.00 price objective on shares of St. Jude Medical in a report on Thursday, July 21st. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of St. Jude Medical in a report on Sunday, July 17th. Twenty-two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. St. Jude Medical has a consensus rating of “Hold” and an average price target of $75.93.

The company has a market capitalization of $24.14 billion and a P/E ratio of 36.40. The firm has a 50-day moving average of $79.22 and a 200 day moving average of $65.82.

St. Jude Medical (NYSE:STJ) last issued its earnings results on Wednesday, July 20th. The medical technology company reported $1.06 EPS for the quarter, hitting the consensus estimate of $1.06. The company had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.55 billion. During the same quarter in the previous year, the firm posted $1.07 earnings per share. St. Jude Medical’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, equities research analysts forecast that St. Jude Medical Inc. will post $4.06 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, July 29th. Shareholders of record on Thursday, June 30th were given a dividend of $0.31 per share. The ex-dividend date of this dividend was Tuesday, June 28th. This represents a $1.24 annualized dividend and a dividend yield of 1.49%.

Several large investors recently modified their holdings of the company. BlackRock Advisors LLC raised its stake in shares of St. Jude Medical by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 2,322,921 shares of the medical technology company’s stock valued at $143,486,000 after buying an additional 15,602 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in St. Jude Medical by 32.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 823,890 shares of the medical technology company’s stock valued at $50,894,000 after buying an additional 199,858 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in St. Jude Medical by 2.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 35,027 shares of the medical technology company’s stock valued at $2,164,000 after buying an additional 911 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its stake in St. Jude Medical by 6.9% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 54,103 shares of the medical technology company’s stock valued at $3,343,000 after buying an additional 3,484 shares in the last quarter. Finally, I.G. Investment Management LTD. raised its stake in St. Jude Medical by 29.7% in the fourth quarter. I.G. Investment Management LTD. now owns 228,600 shares of the medical technology company’s stock valued at $14,121,000 after buying an additional 52,300 shares in the last quarter.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.